Metoclopramide as Treatment of Clozapine-induced Hypersalivation
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable
adverse effect of clozapine therapy that can lead to noncompliance. Until now there is no
effective enough treatment for this side effect.
Previous studies demonstrated that different medications from the substitute benzamide
derivatives group: amisulpride, sulpiride (higher selective binding to the D2/D3 dopamine
receptor) and moclobemide (reversible inhibitor of monoamine oxidase A, which inhibits the
deamination of serotonin, norepinephrine and dopamine) may be effective as a treatment of
clozapine-induced hypersalivation (CIH). Moreover, there is another substitute benzamide
derivative: metoclopramide (dopamine D2 antagonist, usually used as antiemetic medication in
general medicine). The investigators hypothesis assumes that anti-salivation effect
characterizes the whole group of benzamide.
The aim of this study was to examine the efficacy of metoclopramide as an optional
possibility for management of CIH.